Company / Operating Income
Alaunos Therapeutics, Inc. Operating Income History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$4.8M
FY2025
5-year range
-$80.4M / -$4.8M
FY2021-FY2025
Trend
+86.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has increased for 4 consecutive years, from -$80M in FY2021 to -$5M in FY2025.
Based on SEC 10-K filings.
-$5M in FY2025.
Improved from -$35M to -$5M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Alaunos Therapeutics, Inc.'s operating income has grown for 4 consecutive years.
- In FY2025, operating income increased 86.0% year-over-year.
- Lowest operating income in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.8M | +86.0% |
| FY2024 | -$34.3M | +2.4% |
| FY2023 | -$35.1M | +54.7% |
| FY2022 | -$77.5M | +3.5% |
| FY2021 | -$80.4M | -49.1% |
| FY2020 | -$53.9M | -0.8% |
| FY2019 | -$53.5M | +67.6% |
| FY2018 | -$165.3M | -131.5% |
| FY2013 | -$71.4M | -190.9% |
| FY2012 | -$24.5M | -102.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026